var data={"title":"Cinacalcet: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cinacalcet: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5903?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cinacalcet-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cinacalcet: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151617\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Sensipar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5062253\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Sensipar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151636\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Calcimimetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151619\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperparathyroidism, primary:</b> Oral: Initial: 30 mg twice daily; increase dose incrementally every 2 to 4 weeks (to 60 mg twice daily, 90 mg twice daily, and 90 mg 3 or 4 times daily) as necessary to normalize serum calcium levels.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperparathyroidism, secondary:</b> Oral: Initial: 30 mg once daily; increase dose incrementally every 2 to 4 weeks (to 60 mg once daily, 90 mg once daily, 120 mg once daily, and 180 mg once daily) as necessary to maintain intact parathyroid hormone (iPTH) level between 150 to 300 pg/mL. May be used alone or in combination with vitamin D and/or phosphate binders.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parathyroid carcinoma:</b> Oral: Initial: 30 mg twice daily; increase dose incrementally every 2 to 4 weeks (to 60 mg twice daily, 90 mg twice daily, and 90 mg 3 to 4 times daily) as necessary to normalize serum calcium levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151620\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151621\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151622\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate to severe impairment (Child-Pugh class B or C): There are no specific dosage adjustments provided in the manufacturer's labeling; exposure and half-life of cinacalcet is increased. Dosage adjustments may be necessary based on serum calcium, serum phosphorus, and/or intact parathyroid hormone (iPTH).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151637\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Dosage adjustment for hypocalcemia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If iPTH &lt;150 pg/mL: Reduce dose or discontinue cinacalcet and/or vitamin D.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperparathyroidism, secondary:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If serum calcium &gt;7.5 mg/dL but &lt;8.4 mg/dL <b>or</b> if hypocalcemia symptoms occur: Use calcium-containing phosphate binders and/or vitamin D to raise calcium levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If serum calcium &lt;7.5 mg/dL <b>or</b> if hypocalcemia symptoms persist and the dose of vitamin D cannot be increased: Withhold cinacalcet until serum calcium &ge;8 mg/dL and/or symptoms of hypocalcemia resolve. Reinitiate cinacalcet at the next lowest dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151594\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sensipar: 30 mg, 60 mg, 90 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151582\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151597\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with food or shortly after a meal. Do not chew, crush, or divide tablet; administer whole.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151596\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperparathyroidism, primary:</b> Treatment of hypercalcemia in adults with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperparathyroidism, secondary:</b> Treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) on dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parathyroid carcinoma:</b> Treatment of hypercalcemia in adults with parathyroid carcinoma.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151586\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Paresthesia (14% to 29%), headache (&le;21%), fatigue (12% to 21%), depression (10% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypocalcemia (&lt;8.4 mg/dL: 6% to 75%; &lt;7.5 mg/dL: 29% to 33%), dehydration (&le;24%), hypercalcemia (12% to 21%), hypoparathyroidism (intact parathyroid hormone &lt;100 pg/mL: &le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (30% to 66%), vomiting (26% to 52%), diarrhea (21%), anorexia (6% to 21%), constipation (5% to 18%), abdominal pain (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (6% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Bone fracture (12% to 21%), muscle spasm (11% to 18%), arthralgia (6% to 17%), weakness (5% to 17%), myalgia (15%), back pain (12%), limb pain (10% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (13%), cough (12%), upper respiratory tract infection (8% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (7% to 10%), noncardiac chest pain (6%), seizure (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperkalemia (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Upper abdominal pain (8%), dyspepsia (7%), decreased appetite (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Localized infection (dialysis access site; 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Hematologic &amp; oncologic: Upper gastrointestinal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Adynamic bone disease, angioedema, cardiac arrhythmia, cardiac failure, gastrointestinal hemorrhage, hypotension (idiosyncratic), prolonged Q-T interval on ECG (secondary to hypocalcemia), skin rash, urticaria, ventricular arrhythmia (secondary to hypocalcemia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151600\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum calcium less than the lower limit of normal range</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151584\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adynamic bone disease: May develop if intact parathyroid hormone (iPTH) levels are suppressed &lt;100 pg/mL; reduce dose or discontinue use of cinacalcet and/or vitamin D if iPTH levels decrease below 150 pg/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: QT prolongation and ventricular arrhythmia secondary to hypocalcemia may occur. Patients with congenital long QT syndrome, history of QT interval prolongation, family history of long QT syndrome or sudden cardiac death, and other conditions that predispose to QT interval prolongation and ventricular arrhythmia may be at increased risk. Closely monitor corrected serum calcium and QT interval. Cases of idiosyncratic hypotension, worsening of heart failure, and/or arrhythmia have been reported in patients with impaired cardiovascular function; may correlate with decreased serum calcium.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: GI bleeding, mostly upper GI bleeding, have been reported (exact cause unknown); patients with risk factors for upper GI bleeding (eg, gastritis, esophagitis, ulcers, severe vomiting) may be at increased risk. Monitor for worsening of common GI adverse reactions of nausea and vomiting and for signs and symptoms of GI bleeding and ulcerations during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypocalcemia: Life-threatening and fatal events associated with hypocalcemia have occurred. Monitor serum calcium and for symptoms of hypocalcemia (eg, muscle spasms, myalgia, paresthesia, seizure, tetany). Use with caution in patients receiving concomitant therapies known to lower serum calcium concentrations. May require treatment interruption, dose reduction, or initiation (or dose increases) of calcium-based phosphate binder and/or vitamin D to raise serum calcium depending on calcium levels or symptoms of hypocalcemia. Do not initiate therapy if the corrected serum calcium is less than the lower limit of normal; corrected serum calcium must be at or above the lower limit of normal prior to initiation, dose increase, or reinitiation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with moderate-to-severe hepatic impairment (Child-Pugh classes B and C); cinacalcet exposure and half-life are increased; monitor serum calcium, serum phosphorus and iPTH closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; seizure threshold is lowered by significant serum calcium reductions. Monitor calcium levels closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not indicated for chronic kidney disease (CKD) patients not receiving dialysis. In the US, the long-term safety and efficacy of cinacalcet has not been evaluated in CKD patients with hyperparathyroidism not requiring dialysis. Although possibly related to lower baseline calcium levels, clinical studies have shown an increased incidence of hypocalcemia (&lt;8.4 mg/dL) in patients not requiring dialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151630\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151588\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8850&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Ajmaline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: If brexpiprazole is to be used together with both a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Substrates (High risk with Inhibitors): CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Tamoxifen.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to moderate CYP2D6 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Reduce the eliglustat dose to 84 mg daily. Avoid use of eliglustat in combination with a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etelcalcetide: Cinacalcet may enhance the hypocalcemic effect of Etelcalcetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.  Management: Consider an alternative for one of the interacting drugs in order to avoid metoprolol toxicity. If the combination must be used, monitor response to metoprolol closely. Metoprolol dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors may increase the serum concentration of Perhexiline.  Management: Consider alternatives to this combination if possible. If combined, monitor for increased perhexiline serum concentrations and toxicities (eg, hypoglycemia, neuropathy, liver dysfunction). Perhexiline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Cinacalcet may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thioridazine: CYP2D6 Inhibitors may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Cinacalcet may increase the serum concentration of Tricyclic Antidepressants.  Management: Seek alternatives when possible. If these combinations are used, monitor closely for increased effects/toxicity and/or elevated serum concentrations (when testing is available) of the tricyclic antidepressant.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151614\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food increases bioavailability. Management: Administer with food or shortly after a meal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151603\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Information related to the use of cinacalcet in pregnant women is limited (Edling 2014; Horius 2009; Nadarasa 2014; Rey 2016; Vera 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151604\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if cinacalcet is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151592\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor for signs/symptoms of hypocalcemia. Monitor serum calcium and iPTH concentrations closely in patients on concurrent CYP3A4 inhibitors or with seizure disorders; monitor serum calcium, iPTH, and serum phosphorous concentrations closely in patients with hepatic moderate to severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperparathyroidism, secondary: Serum calcium and phosphorus levels prior to initiation and within a week of initiation and frequently during dose titration; iPTH should be measured 1 to 4 weeks after initiation or dosage adjustment (wait at least 12 hours after dose before drawing iPTH levels). After the maintenance dose is established, obtain serum calcium levels monthly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parathyroid carcinoma and hyperparathyroidism, primary: Serum calcium levels prior to initiation and within a week of initiation or dosage adjustment; once maintenance dose is established, obtain serum calcium every 2 months.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151595\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CKD K/DOQI guidelines definition of stages; chronic disease is kidney damage or GFR &lt;60 mL/minute/1.73 m<sup>2</sup> for &ge;3 months:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stage 2: GFR 60 to 89 mL/minute/1.73 m<sup>2</sup> (kidney damage with mild decrease GFR)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stage 3: GFR 30 to 59 mL/minute/1.73 m<sup>2</sup> (moderate decrease GFR)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stage 4: GFR 15 to 29 mL/minute/1.73 m<sup>2</sup> (severe decrease GFR)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stage 5: GFR &lt;15 mL/minute/1.73 m<sup>2</sup> or dialysis (kidney failure)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Target range for iPTH: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stage 3 CKD: 35 to 70 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stage 4 CKD: 70 to 110 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stage 5 CKD: 150 to 300 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum phosphorus: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stage 3 and 4 CKD: &ge;2.7 to &lt;4.6 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stage 5 CKD: 3.5 to 5.5 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum calcium-phosphorus product: Adults: Stage 3 to 5 CKD: &lt;55 mg<sup>2</sup>/dL<sup>2</sup></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151583\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Increases the sensitivity of the calcium-sensing receptor on the parathyroid gland thereby, concomitantly lowering parathyroid hormone (PTH), serum calcium, and serum phosphorus levels, preventing progressive bone disease and adverse events associated with mineral metabolism disorders. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151599\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~1,000 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~93% to 97% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (extensive) via CYP3A4, 2D6, 1A2; forms inactive metabolites </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: 30 to 40 hours; moderate hepatic impairment: 65 hours; severe hepatic impairment: 84 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: ~2 to 6 hours; increased with food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine ~80% (as metabolites); feces ~15%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F151602\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sensipar Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $968.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (30): $1,936.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (30): $2,904.12</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539832\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Autraxil (AR);</li>\n      <li>Calcipar (PH);</li>\n      <li>Capicet (IN);</li>\n      <li>Cencipal (HU);</li>\n      <li>Ceracal (IN);</li>\n      <li>Cineset (TR);</li>\n      <li>Geser (CL);</li>\n      <li>Kalsiset (TR);</li>\n      <li>Micalcet (CZ);</li>\n      <li>Mimpara (AE, AR, AT, BE, BG, BH, BR, CH, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HN, HR, HU, IE, IL, IS, IT, JO, KW, LB, LT, LU, LV, MT, MX, NI, NL, NO, PA, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TR, UA);</li>\n      <li>Mimpoara (CO);</li>\n      <li>Parareg (HU, NL);</li>\n      <li>Regpara (CN, HK, JP, KR, MY, SG, TH, TW);</li>\n      <li>Sensipar (AU, GR, NZ, ZA);</li>\n      <li>Tenalcet (AR);</li>\n      <li>Tyrodin (BD);</li>\n      <li>Viscap (TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Block GA, Martin KJ, de Francisco AL, et al, &ldquo;Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis,&rdquo; <i>N Engl J Med</i>, 2004, 350(15):1516-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/15071126/pubmed\" target=\"_blank\" id=\"15071126\">15071126</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edling KL, Korenman SG, Janzen C, et al. A pregnant dilemma: primary hyperparathyroidism due to parathyromatosis in pregnancy. <i>Endocr Pract</i>. 2014;20(2):e14-e17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/24013984/pubmed\" target=\"_blank\" id=\"24013984\">24013984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eknoyan G, Levin A, and Levin NW, &ldquo;Bone Metabolism and Disease in Chronic Kidney Disease,&rdquo; <i>Am J Kidney Dis</i>, 2003, 42(4 Suppl 3):1-201.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horjus C, Groot I, Telting D, et al. Cinacalcet for hyperparathyroidism in pregnancy and puerperium. <i>J Pediatr Endocrinol Metab</i>. 2009;22(8):741-749.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/19845125/pubmed\" target=\"_blank\" id=\"19845125\">19845125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marcocci C, Chanson P, Shoback D, et al, &ldquo;Cinacalcet Reduces Serum Calcium Concentrations in Patients With Intractable Primary Hyperparathyroidism,&rdquo; <i>J Clin Endocrinol Metab</i>, 2009, 94(8):2766-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/19470620/pubmed\" target=\"_blank\" id=\"19470620\">19470620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moe SM, Cunningham J, Bommer J, et al, &ldquo;Long-Term Treatment of Secondary Hyperparathyroidism With the Calcimimetic Cinacalcet HCl,&rdquo; <i>Nephrol Dial Transplant</i>, 2005, 20(10):2186-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/16030053/pubmed\" target=\"_blank\" id=\"16030053\">16030053</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nadarasa K, Bailey M, Chahal H, et al. The use of cinacalcet in pregnancy to treat a complex case of parathyroid carcinoma. <i>Endocrinol Diabetes Metab Case Rep</i>. 2014;2014:140056.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/25298882/pubmed\" target=\"_blank\" id=\"25298882\">25298882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Guideline 13: Treatment of Bone Disease in Chronic Kidney Disease. Available at http://www2.kidney.org/professionals/KDOQI/guidelines_bone/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rey E, Jacob CE, Koolian M, Morin F. Hypercalcemia in pregnancy &mdash; a multifaceted challenge: case reports and literature review. <i>Clin Case Rep</i>. 2016;4(10):1001-1008.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/27761256/pubmed\" target=\"_blank\" id=\"27761256\">27761256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sensipar (cinacalcet) [prescribing information]. Thousand Oaks, CA: Amgen Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silverberg SJ, Rubin MR, Faiman C, et al, &ldquo;Cinacalcet Hydrochloride Reduces the Serum Calcium Concentration in Inoperable Parathyroid Carcinoma,&rdquo; <i>J Clin Endocrinol Metab</i>, 2007, 92(10):3803-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/17666472/pubmed\" target=\"_blank\" id=\"17666472\">17666472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vera L, Oddo S, Di Iorgi N, Bentivoglio G, Giusti M. Primary hyperparathyroidism in pregnancy treated with cinacalcet: a case report and review of the literature. <i>J Med Case Rep</i>. 2016;10(1):361.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cinacalcet-drug-information/abstract-text/27998296/pubmed\" target=\"_blank\" id=\"27998296\">27998296</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8850 Version 156.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F151617\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5062253\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F151636\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F151619\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F151620\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F151621\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F151622\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F151637\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F151594\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F151582\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F151597\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F151596\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F151586\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F151600\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F151584\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F151630\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F151588\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F151614\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F151603\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F151604\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F151592\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F151595\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F151583\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F151599\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F151602\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539832\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8850|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cinacalcet-patient-drug-information\" class=\"drug drug_patient\">Cinacalcet: Patient drug information</a></li></ul></div></div>","javascript":null}